We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Trimel Pharmaceuticals Facility Receives GMP Compliance Designation

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Trimel Pharmaceuticals Facility Receives GMP Compliance Designation"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Trimel intends to use the Dunwin facility to manufacture clinical supplies for both of its CompleoTRT and TBS-2 (Anorgasmia) products as well as the balance of its pipeline including those compounds under development with the TriVair pulmonary delivery system. Trimel has demonstrated to Health Canada that the activities it conducts at its Dunwin facility conform to the Food and Drugs Act and its associated regulations.

"Having Health Canada approve our facility is an important validation of our business strategy." said Bruce D. Brydon, Chairman and Chief Executive Officer of Trimel. "Trimel has now achieved the first step toward the commercial supply of our products with the strictest adherence to quality."